Telix Pharmaceuticals reported asset growth of 17.38% for the quarter ended Dec 2025. These growth metrics cover 2 quarters of results from Dec 2024 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Growth Metrics | Dec2024 | Dec2025 |
|---|---|---|
| Growth Ratios | ||
| Assets Growth (1y) | 275.25% | 17.38% |
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | 479.03% | -69.46% |
| Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) | 246.25% | 113.24% |
| Total Debt Growth (1y) | 6,151.08% | 8.50% |